Work

Supplementary Table 1 from A Phase I Clinical Trial of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Patients with Recurrent Gynecologic Cancer

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 51K, Patients were then assigned into one of three Ad5.SSTR/TK.RGD dose cohorts ranging from 1 x 109 vp/d to 1 x 1012 vp/d (6 x 107 pfu/d to 6 x 1010 pfu/d). This dose administration strategy has been validated in our preclinical studies; assigned Ad5.SSTR/TK

DOI: 10.1158/1078-0432.22444517.v1

Authors: Kenneth H. Kim, Igor Dmitriev, Janis P. O'Malley, Minghui Wang, Souheil Saddekni, Zhiying You, Meredith A. Preuss, Raymond D. Harris, Rosemarie Aurigemma, Gene P. Siegal, Kurt R. Zinn, David T. Curiel, Ronald D. Alvarez

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362427426

Cites:

Cited by:

Related to: 10